<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255096</url>
  </required_header>
  <id_info>
    <org_study_id>NP39461</org_study_id>
    <secondary_id>2017-000357-39</secondary_id>
    <nct_id>NCT03255096</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6</brief_title>
  <official_title>Open-Label, Dose Escalation/Expansion Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and/or High-Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 Gene Rearrangements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and clinical activity of&#xD;
      RO6870810 in combination with venetoclax and when co-administered with rituximab in&#xD;
      participants with relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and/or&#xD;
      high-grade B-cell lymphoma with myelocytomatosis oncogene (MYC) and/or B-cell lymphoma 2&#xD;
      (BCL2) and/or B-cell lymphoma 6 (BCL6) gene rearrangements (HGBL-DH/TH).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Actual">July 3, 2019</completion_date>
  <primary_completion_date type="Actual">July 3, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Dose-Limiting Toxiciities (DLT)- Part 1</measure>
    <time_frame>Cycle (C) 1 (21 days)</time_frame>
    <description>DLT is defined as any of the toxicities- occurs within the first cycle for which the participant receives the full intended combination doses and number of administrations; is considered to be related to study treatment by the investigator; is not attributed to disease progression or another clearly identifiable cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) - Part 1</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Vital Signs, Physical Examination, Clinical Laboratory Results and Electrocardiogram (ECG) Findings- Part 1</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response (CR) Rate as Determined by Independent Radiological Central Review (ICR) Using Modified Lugano Response Criteria- Recommended Dose (RD) Expansion - Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response (OR) Rate as Determined by Independent Radiological Central Review (ICR) Using Modified Lugano Response Criteria- RD Expansion - Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) - Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Vital Signs, Physical Examination, Clinical Laboratory Results and Electrocardiogram (ECG) Findings- Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Serum Concentration (Cmin) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Cycle 2 and all other subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration (tmax) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vd) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate as Determined by the Investigator Based on the Modified Lugano Response Criteria- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate, as Determined by the ICR and by the Investigator on the Basis of CT Scans Alone- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate, as Determined by the ICR and by the Investigator on the Basis of Modified Lugano Response Criteria- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate, as Determined by the ICR and by the Investigator on the Basis of CT Scans Alone- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS)- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t1/2) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Ant-Drug Antibodies (ADA) Against Rituximab - Part 1 and Part 2</measure>
    <time_frame>Pre-dose, End of Infusion Day 1 Cycle 1; Pre-dose Day 1 Cycle 2, 3, 4 , 6 and all other even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <condition>High-Grade B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Phase (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either RO6870810 and venetoclax or RO6870810 and venetoclax along with rituximab until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO6870810 and venetoclax along with rituximab (or RO6870810 and venetoclax, if the combination of the 3 drugs is not tolerable) at a recommended dose established in dose escalation phase until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6870810</intervention_name>
    <description>RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.</description>
    <arm_group_label>Dose Escalation Phase (Part 1)</arm_group_label>
    <arm_group_label>Expansion Phase (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.</description>
    <arm_group_label>Dose Escalation Phase (Part 1)</arm_group_label>
    <arm_group_label>Expansion Phase (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab intravenously (IV) at dose of 375 mg/m^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.</description>
    <arm_group_label>Dose Escalation Phase (Part 1)</arm_group_label>
    <arm_group_label>Expansion Phase (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.&#xD;
&#xD;
          -  Life expectancy &gt;3 months as per investigator's assessment.&#xD;
&#xD;
          -  Part 1 and Part 2 Group 1: Participantts with diffuse large B-cell lymphoma (DLBCL)&#xD;
             relapsed or refractory to ≥ 1 course of chemotherapy including an anti-CD20 monoclonal&#xD;
             antibody, and not eligible for autologous stem cell transplantation (ASCT) (including&#xD;
             due to chemorefractory disease). Participants with transformed FL are eligible,&#xD;
             provided DLBCL or HGBL-DH/TH histology is biopsy-confirmed prior to study entry and a&#xD;
             treatment regimen as described above has been administered. The Sponsor retains the&#xD;
             option to limit the number of participants enrolled with transformed FL.&#xD;
&#xD;
        Part 2, Group 2: Patients identified with DE-DLBCL (expression MYC ≥40%, BCL2 &gt; 50%) and or&#xD;
        HGBL-DH/TH, relapsed or refractory to &gt;= 1 course of chemotherapy including an anti-CD20&#xD;
        monoclonal antibody, and not eligible for ASCT (including due to chemorefractory disease).&#xD;
        Patients with transformed follicular lymphoma (FL) are eligible, provided DE-DLBCL and/or&#xD;
        HGBL-DH/TH histology is biopsy-confirmed prior to study entry and a treatment regimen as&#xD;
        described above has been administered. The Sponsor retains the option to limit the number&#xD;
        of participants enrolled with transformed FL.&#xD;
&#xD;
          -  Part 1 and Part 2: Willing to provide the protocol specified tumor biopsy(ies): at&#xD;
             screening a fresh biopsy (if no archival biopsy tissue of less than 3 months prior to&#xD;
             treatment and without intercurrent treatment is available); Part 2: Willing to provide&#xD;
             an additional biopsy on Cycle 2 Day 15 (+ 2 days).&#xD;
&#xD;
          -  Acceptable liver function, as specified below:&#xD;
&#xD;
               -  Total bilirubin ≤ 2 times upper limit of normal (ULN). (Participants with known&#xD;
                  Gilbert's disease who has serum bilirubin ≤ 3 × ULN may be enrolled).&#xD;
&#xD;
               -  Aspartate transaminase (AST; SGOT), alanine transaminase (ALT; SGPT) ≤ 2.5 × ULN,&#xD;
                  (or ≤ 5 × ULN if tumor involvement (liver) is present).&#xD;
&#xD;
               -  Gamma-glutamyl transferase (GGT) alkaline phosphatase ≤ 2.5 × ULN.&#xD;
&#xD;
          -  Acceptable renal function, as specified below:&#xD;
&#xD;
             • Creatinine clearance (CrCl) calculated by Cockroft-Gault formula of ≥ 60 mL/min.&#xD;
&#xD;
          -  Acceptable hematologic status (growth factors cannot be used within the previous 7&#xD;
             days), as specified below:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1000 cells/μL&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Platelet count ≥ 75,000 (platelets/μL)&#xD;
&#xD;
          -  Uncontrolled symptomatic hypercalcemia.&#xD;
&#xD;
          -  Acceptable coagulation status, as specified below:&#xD;
&#xD;
               -  Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.2 × ULN (unless&#xD;
                  receiving anticoagulation therapy, if receiving anticoagulation therapy,&#xD;
                  eligibility will be based upon international normalized ratio [INR]).&#xD;
&#xD;
               -  INR ≤ 1.6 (unless receiving anticoagulation therapy).&#xD;
&#xD;
               -  If receiving warfarin: INR ≤ 3.0 and no active bleeding (i.e., no bleeding within&#xD;
                  14 days prior to first dose of study therapy).&#xD;
&#xD;
          -  Acceptable method of contraception&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Current central nervous system (CNS) lymphoma or leptomeningeal infiltration.&#xD;
&#xD;
          -  New York Heart Association (NYHA) Class III or IV cardiac disease, myocardial&#xD;
             infarction, within the past 6 months, unstable arrhythmia, or known pericardial&#xD;
             disease.&#xD;
&#xD;
          -  Fredericia-corrected QT interval (QTcF) &gt;470 msec (female) or &gt;450 msec (male), or&#xD;
             history of congenital long QT syndrome.&#xD;
&#xD;
          -  Any electrocardiogram (ECG) abnormality, which in the opinion of the Investigator&#xD;
             would preclude safe participation in the study.&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study&#xD;
             entry requiring systemic therapy.&#xD;
&#xD;
          -  Clinically important respiratory impairment&#xD;
&#xD;
          -  Grade ≥ 3 sensory or motor neuropathy.&#xD;
&#xD;
          -  Any Grade &gt;1 (according to the NCI CTCAE 4.03) adverse reaction unresolved from&#xD;
             previous treatments and not readily managed and controlled with supportive care.&#xD;
&#xD;
          -  Serious non-malignant disease that could compromise protocol objectives in the opinion&#xD;
             of the Investigator and/or the Sponsor.&#xD;
&#xD;
          -  History of progressive multifocal leukoencephalopathy (PML).&#xD;
&#xD;
          -  History of other malignancy within 2 years prior to screening, except for ductal&#xD;
             carcinoma in situ not requiring chemotherapy, appropriately treated carcinoma in situ&#xD;
             of the cervix, non-melanoma skin carcinoma, low-grade, localized prostate cancer&#xD;
             (Gleason score ≤ 7) not requiring treatment or appropriately treated Stage I uterine&#xD;
             cancer.&#xD;
&#xD;
          -  Completion of ASCT within 100 days prior to Day 1 of Cycle1.&#xD;
&#xD;
          -  Prior standard or investigational anti-cancer therapy, as specified below:&#xD;
&#xD;
               -  Radio-immunoconjugate 4 weeks or 5 half-lives, whichever is longer prior to Day 1&#xD;
                  of Cycle 1.&#xD;
&#xD;
               -  Monoclonal antibody or antibody-drug conjugate (ADC) therapy within 3 weeks prior&#xD;
                  to Day 1 of Cycle 1.&#xD;
&#xD;
               -  Radiotherapy, chemotherapy, or targeted small-molecule therapy within 2 weeks&#xD;
                  prior to Day 1 of Cycle 1.&#xD;
&#xD;
               -  CAR T-cell therapy 30 days prior to Day 1 of Cycle 1.&#xD;
&#xD;
          -  History of major solid organ transplant (i.e., heart, lungs, liver and kidney).&#xD;
&#xD;
          -  History of an allogeneic bone marrow transplant.&#xD;
&#xD;
          -  Major surgical procedure within 28 days prior to Day 1 of Cycle 1.&#xD;
&#xD;
          -  Treatment with systemic corticosteroids ≥ 20 mg/day prednisone or equivalent, for&#xD;
             non-lymphoma treatment reasons. For lower acceptable doses, documentation of a stable&#xD;
             dose for at least 4 weeks prior to Day 1 of Cycle 1 is required.&#xD;
&#xD;
             18. Treatment with strong to moderate CYP3A inhibitors or moderate CYP3A inducers&#xD;
             within 7 days prior to the first dose of study treatment.&#xD;
&#xD;
          -  Treatment with strong CYP3A inducers within 14 days prior to the first dose of study&#xD;
             treatment of RO6870810/venetoclax.&#xD;
&#xD;
          -  Consumption of grapefruits, grapefruit products, Seville oranges (including marmalade&#xD;
             that contains Seville oranges), or star fruit within 3 days prior to the first dose of&#xD;
             venetoclax.&#xD;
&#xD;
          -  Participants who are currently receiving any other investigational agent ((other than&#xD;
             anti-cancer therapy as specified in exclusion criteria number 13) or have received an&#xD;
             investigational agent within 30 days or 5 half-lives prior to Day 1 of Cycle 1,&#xD;
             whichever is longer.&#xD;
&#xD;
          -  Prior treatment with small molecule bromodomain and extra terminal (BET) family&#xD;
             inhibitor.&#xD;
&#xD;
          -  Known to be human immunodeficiency virus (HIV) positive.&#xD;
&#xD;
          -  Presence of positive test results for hepatitis B surface antigen (HBsAg) or hepatitis&#xD;
             C antibodies (HcAb) (for participants receiving regimen including rituximab)&#xD;
&#xD;
          -  Pregnant or breastfeeding female.&#xD;
&#xD;
          -  Significant allergy to a biological pharmaceutical therapy that, in the opinion of the&#xD;
             Investigator, poses an increased risk to the participant.&#xD;
&#xD;
          -  Uncontrolled cancer pain. Participants requiring pain medication must be on a stable&#xD;
             regimen at study entry. Symptomatic lesions amenable to palliative radiotherapy should&#xD;
             be treated prior to enrollment.&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reaction to humanized or murine monoclonal&#xD;
             antibodies (for participants receiving regimen including rituximab).&#xD;
&#xD;
          -  Known sensitivity or allergy to murine products or any component of RO6870810,&#xD;
             venetoclax, or rituximab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Chair</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute - Blythe</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre-East Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet; Hæmatologisk Klinik</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START Madrid-FJD, Hospital Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

